Yesterday, June 6, 2016, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $185.85 to $2,531,705.11.

Highlighted Stocks Traded by Insiders:

Watts Water Technologies (WTS) - FREE Research Report

Horne Timothy P, who is 10% Owner at Watts Water Technologies, sold 25,000 shares at $57.50 on June 6, 2016. Following this transaction, the 10% Owner owned 0 shares meaning that the stake was reduced by 100% with the 25,000-share transaction.

The shares most recently traded at $58.23, up $0.73, or 1.25% since the insider transaction. Historical insider transactions for Watts Water Technologies go as follows:

  • 4-Week # shares sold: 30,160
  • 12-Week # shares sold: 30,160
  • 24-Week # shares sold: 32,160

The average volume for Watts Water Technologies has been 112,300 shares per day over the past 30 days. Watts Water Technologies has a market cap of $2.0 billion and is part of the industrial goods sector and industrial industry. Shares are up 16.77% year-to-date as of the close of trading on Monday.

Watts Water Technologies, Inc. designs, manufactures, and sells products and solutions that manage and conserve the flow of fluids and energy into, through and out of buildings in the residential and commercial markets. The stock currently has a dividend yield of 1.25%. Currently, there are 5 analysts who rate Watts Water Technologies a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WTS - FREE

TheStreet Quant Ratings

rates Watts Water Technologies as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full

Watts Water Technologies Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ironwood Pharmaceuticals (IRWD) - FREE Research Report

Olanoff Lawrence S, who is Director at Ironwood Pharmaceuticals, sold 2,200 shares at $12.92 on June 6, 2016. Following this transaction, the Director owned 32,505 shares meaning that the stake was reduced by 6.34% with the 2,200-share transaction.

The shares most recently traded at $12.99, up $0.07, or 0.54% since the insider transaction. Historical insider transactions for Ironwood Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 4,410
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 4,410
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 14,125

The average volume for Ironwood Pharmaceuticals has been 1.6 million shares per day over the past 30 days. Ironwood Pharmaceuticals has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 14.24% year-to-date as of the close of trading on Monday.

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. Currently, there are 4 analysts who rate Ironwood Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Recommends

Exclusive Offer: Get the latest Stock Analysis on IRWD - FREE

TheStreet Quant Ratings

rates Ironwood Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally high debt management risk. Get the full

Ironwood Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Salem Media Group (SALM) - FREE Research Report

Evans David, who is President - New Media at Salem Media Group, sold 12,558 shares at $6.90 on June 6, 2016. Following this transaction, the President - New Media owned 61,496 shares meaning that the stake was reduced by 16.96% with the 12,558-share transaction.

The shares most recently traded at $6.94, up $0.04, or 0.58% since the insider transaction. Historical insider transactions for Salem Media Group go as follows:

  • 4-Week # shares bought: 2,310
  • 4-Week # shares sold: 15,899
  • 12-Week # shares bought: 2,310
  • 12-Week # shares sold: 15,899
  • 24-Week # shares bought: 2,310
  • 24-Week # shares sold: 15,899

The average volume for Salem Media Group has been 57,400 shares per day over the past 30 days. Salem Media Group has a market cap of $177.6 million and is part of the services sector and media industry. Shares are up 39.36% year-to-date as of the close of trading on Monday.

Salem Media Group, Inc. operates as a multi-media company in the United States. It operates in three segments: Broadcast, Digital Media, and Publishing. The stock currently has a dividend yield of 3.74%. The company has a P/E ratio of 26.8. Currently, there is 1 analyst who rates Salem Media Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SALM - FREE

TheStreet Quant Ratings

rates Salem Media Group as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins. Get the full

Salem Media Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.